Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N,N-Dimethyltryptamine

            Therapeutic Area: Neurology Product Name: AP-188

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 17, 2021

            Details:

            The Company announced preclinical study of AP-188 (“N, N-Dimethyltryptamine) in stroke patients which is now underway with Charles River Laboratories.The planned Phase 1 study will investigate the safety, tolerability and pharmacokinetics of intravenous DMT infusion.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N,N-Dimethyltryptamine

            Therapeutic Area: Neurology Product Name: AP-188

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 17, 2021

            Details:

            Algernon has filed new provisional patents for new forms of N,N-Dimethyltryptamine (DMT), in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and Constraint Induced Movement Therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N,N-Dimethyltryptamine

            Therapeutic Area: Neurology Product Name: AP-188

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2021

            Details:

            28% and 32% significant reductions in first and total strokes, respectively, Showed with VASCEPA compared to placebo and reductions in fi